Douglas K. Bratton and affiliated entities filed an amended Schedule 13G reporting a massive reduction in beneficial ownership of Aquestive Therapeutics, from over 8 million shares to approximately 691,873 shares (0.6% of outstanding). The decrease was driven by the distribution of all shares held by MonoLine RX II, MonoLine RX III, MonoLine RX, MonoLine Partners, and MonoSol RX Genpar to their respective owners between October 2 and October 7, 2026, effectively unwinding a large concentrated position.
Price Chart
Executive Summary
Douglas K. Bratton and affiliated entities filed an amended Schedule 13G reporting a massive reduction in beneficial ownership of Aquestive Therapeutics, from over 8 million shares to approximately 691,873 shares (0.6% of outstanding). The decrease was driven by the distribution of all shares held by MonoLine RX II, MonoLine RX III, MonoLine RX, MonoLine Partners, and MonoSol RX Genpar to their respective owners between October 2 and October 7, 2026, effectively unwinding a large concentrated position.
Key Facts
- Douglas K. Bratton's beneficial ownership dropped to 691,873 shares, or 0.6% of outstanding shares.
- MonoLine RX II, L.P. distributed 3,468,747 shares to its owners between October 2 and October 7, 2026.
- MonoLine RX III, L.P. distributed 2,657,943 shares to its owners between October 2 and October 7, 2026.
- MonoLine RX, L.P. distributed 1,688,639 shares to its owners between October 2 and October 7, 2026.
- MonoLine Partners, L.P. distributed 1,948,578 shares to its owners on October 2, 2026.
- MonoSol RX Genpar, L.P. distributed 47,051 shares to its owners between October 2 and October 7, 2026.
- Bratton Capital Management, L.P. retains 390,795 shares (0.3%) and Bratton Capital Inc. retains 391,670 shares (0.3%).
- Bratton Family Partners L.P. retains 33,727 shares (0.03%).
Financial Impact
Approximately 8.8 million shares (approximately 8.8 million shares) distributed out of the Bratton/MonoLine group, representing a reduction from over 8 million shares to approximately 691,873 shares. No dollar value stated in filing.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000897423-26-000124 |
| Document: 0000897423-26-000124-index.html | 0000897423-26-000124 |
| Document: 0000897423-26-000124.txt | 0000897423-26-000124 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $3.97 (−2.22%) |
Oct 15, 2026 11d ago | Press Release | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $3.97 (−2.22%) |
Oct 14, 2026 12d ago | 8-K | $4.61 $4.08 | ▼ −11.50% | ▼ −11.95% | $3.97 (−13.88%) |
Oct 7, 2026 19d ago | SC 13G | $4.62 $4.61 | ▼ −0.22% | ▲ +0.76% | $3.97 (−14.07%) |
Oct 7, 2026 19d ago | SC 13G/A | $4.62 $4.61 | ▲ +0.22% | ▼ −0.76% | $3.97 (+14.07%) |
Sep 29, 2026 27d ago | 8-K | $4.67 $4.61 | ▼ −1.28% | ▼ −3.23% | $3.97 (−14.99%) |
Sep 25, 2026 4w ago | 8-K | $4.68 $4.55 | ▼ −2.78% | ▼ −2.56% | $3.97 (−15.17%) |
Sep 17, 2026 5w ago | 8-K | $4.66 $4.82 | ▲ +3.43% | ▲ +2.83% | $3.97 (−14.81%) |
Sep 16, 2026 5w ago | Insider Cluster | $4.82 $4.70 | ▼ −2.49% | ▼ −5.05% | $3.97 (−17.63%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.29 $4.80 | ▲ +11.89% | ▲ +13.08% | $3.97 (−7.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers